• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma.

作者信息

Shan Xinhe, Long Qi, Garfall Alfred L, Susanibar-Adaniya Sandra P

机构信息

Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA.

Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Blood Cancer J. 2023 May 22;13(1):86. doi: 10.1038/s41408-023-00855-1.

DOI:10.1038/s41408-023-00855-1
PMID:37217520
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10203273/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/10203273/da8ad79602df/41408_2023_855_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/10203273/da8ad79602df/41408_2023_855_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2530/10203273/da8ad79602df/41408_2023_855_Fig1_HTML.jpg

相似文献

1
High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma.高SOX2表达与新诊断的多发性骨髓瘤患者的不良生存相关。
Blood Cancer J. 2023 May 22;13(1):86. doi: 10.1038/s41408-023-00855-1.
2
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies.基因表达谱可预测接受新型疗法治疗的新诊断骨髓瘤患者的无复发生存期和总生存期。
Br J Haematol. 2021 Feb;192(4):e115-e120. doi: 10.1111/bjh.17344. Epub 2021 Jan 24.
3
High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.磷酸化细胞外信号调节激酶（ERK1/2）的高表达与新诊断的多发性骨髓瘤患者的不良预后相关。
Med Sci Monit. 2017 May 30;23:2636-2643. doi: 10.12659/msm.901850.
4
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.多发性骨髓瘤患者在异基因干细胞移植后会产生SOX2特异性自身抗体。
Clin Dev Immunol. 2011;2011:302145. doi: 10.1155/2011/302145. Epub 2011 Nov 15.
5
Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells From Multiple Myeloma Patients By Targeting BMP4 Transcription.上调长链非编码 RNA MEG3 通过靶向 BMP4 转录促进多发性骨髓瘤患者间充质干细胞的成骨分化。
Stem Cells. 2015 Jun;33(6):1985-97. doi: 10.1002/stem.1989.
6
Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.四倍体与多发性骨髓瘤诊断时的不良预后相关。
Am J Hematol. 2019 May;94(5):E117-E120. doi: 10.1002/ajh.25420. Epub 2019 Feb 6.
7
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.新诊断多发性骨髓瘤中 17p 缺失的基线特征、染色体改变和影响预后的治疗。
Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.
8
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.一种用于从 CD138 纯化骨髓瘤细胞中定量检测蛋白质的新型纳米免疫分析方法：生物学和临床应用。
Haematologica. 2018 May;103(5):880-889. doi: 10.3324/haematol.2017.181628. Epub 2018 Mar 15.
9
Heparanase promotes myeloma stemness and in vivo tumorigenesis.肝素酶促进骨髓瘤干细胞特性和体内肿瘤发生。
Matrix Biol. 2020 Jun;88:53-68. doi: 10.1016/j.matbio.2019.11.004. Epub 2019 Dec 5.
10
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.新诊断骨髓瘤的预后预测：1905 试验患者分子谱的荟萃分析。
Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.

本文引用的文献

1
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.抗 BCMA/CD19 CAR T 细胞联合早期免疫调节维持治疗对初始或后线治疗有效的多发性骨髓瘤。
Blood Cancer Discov. 2023 Mar 1;4(2):118-133. doi: 10.1158/2643-3230.BCD-22-0074.
2
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.骨髓肿瘤和免疫细胞的变化与骨髓瘤患者接受 BCMA CAR T 治疗后的缓解持续时间相关。
Blood Cancer Discov. 2022 Nov 2;3(6):490-501. doi: 10.1158/2643-3230.BCD-22-0018.
3
Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
单细胞 RNA 测序揭示复发多发性骨髓瘤的克隆多样性和预后基因。
Clin Transl Med. 2022 Mar;12(3):e757. doi: 10.1002/ctm2.757.
4
Using Propensity Scores for Causal Inference: Pitfalls and Tips.使用倾向得分进行因果推断：陷阱与技巧。
J Epidemiol. 2021 Aug 5;31(8):457-463. doi: 10.2188/jea.JE20210145. Epub 2021 Jun 12.
5
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.MBD3-SOX2轴在泊马度胺治疗后残留骨髓瘤中的作用
Leukemia. 2021 Nov;35(11):3319-3323. doi: 10.1038/s41375-021-01145-0. Epub 2021 Feb 18.
6
Long non-coding RNA Sox2 overlapping transcript (SOX2OT) promotes multiple myeloma progression via microRNA-143-3p/c-MET axis.长非编码 RNA Sox2 重叠转录物 (SOX2OT) 通过 microRNA-143-3p/c-MET 轴促进多发性骨髓瘤进展。
J Cell Mol Med. 2020 May;24(9):5185-5194. doi: 10.1111/jcmm.15171. Epub 2020 Mar 21.
7
EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.EZH2 在多发性骨髓瘤中的过表达：预后价值、与临床特征的相关性及可能的机制。
Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):744-750. doi: 10.1016/j.clml.2019.08.010. Epub 2019 Aug 30.
8
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.抗 CD19 CAR T 细胞联合大剂量美法仑和自体干细胞移植治疗难治性多发性骨髓瘤。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.120505.
9
The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter.多梳抑制复合物蛋白 EZH2 通过结合 PTEN 启动子诱导胃癌细胞上皮-间充质转化和多能表型。
J Hematol Oncol. 2018 Jan 15;11(1):9. doi: 10.1186/s13045-017-0547-3.
10
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.SOX2促进TP53和RB1缺陷型前列腺癌中的谱系可塑性和抗雄激素耐药性。
Science. 2017 Jan 6;355(6320):84-88. doi: 10.1126/science.aah4307.